冠状动脉药物洗脱支架内再狭窄的最新研究进展  

Advances in coronary drug-eluting stent restenosis

作　　者：郝伟 赵晨[1] 胡思宁[1] 贾海波[1] 于波[1] HAO Wei;ZHAO Chen;HU Si-ning;JIA Hai-bo;YU Bo(Department of Cardiology,the Second Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第二医院心内科,黑龙江哈尔滨150001

出　　处：《中国介入心脏病学杂志》2023年第1期63-68,共6页Chinese Journal of Interventional Cardiology

基　　金：黑龙江省自然科学基金研究团队项目(TD2020H001)。

摘　　要：药物洗脱支架(DES)的诞生和不断优化已经大大提高了经皮冠状动脉介入治疗(PCI)的安全性和有效性,但随着病例复杂性的增加和DES的超适应证应用,术后再狭窄率正逐年上升。因此,当前DES时代下,支架内再狭窄(ISR)仍是临床上亟待解决的一大难题。本文将主要就DES置入后ISR发生发展的病理机制、组织病理学及治疗策略的最新研究成果及进展进行综述。The advent and subsequent iterations of drug-eluting stent(DES)technologies have signifi cantly improved the safety and e ffi cacy of percutaneous coronary interventions(PCI).However,with the increasing complexity of cases and off-label use of DES,the restenosis rates with DES are rising year by year.Therefore,in-stent restenosis(ISR)in the current DES era is still a major clinical challenge that needs to be addressed.This paper mainly reviews the latest research fi ndings and progress on the pathological mechanisms,histopathology and treatment strategies of ISR after DES implantation.

关 键 词：经皮冠状动脉介入治疗 支架内再狭窄 药物洗脱支架 药物涂层球囊 

分 类 号：R541[医药卫生—心血管疾病]